Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04081688 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
A Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04081688 is a Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 16 participants.
The verdict
NCT04081688, a Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies such as atezolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies such as varlilumab may induce changes in body?s immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving atezolizumab, varlilumab, and radiation therapy may increase the amount of time the disease is not active or does not spread to another part of the body.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Atezolizumab 1200 MG in 20 ML Injection
- DRUG Varlilumab 3 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04081688
The ClinicalTrials.gov registry entry for NCT04081688 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT04081688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04081688 about?
NCT04081688 is a clinical study titled "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC". This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies such as...
What is the current status of trial NCT04081688?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-09-11. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT04081688?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Atezolizumab 1200 MG in 20 ML Injection (DRUG), Varlilumab 3 mg/kg (DRUG).
Who is sponsoring clinical trial NCT04081688?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.